Summary of Expertise, Experience, Affiliations and Interests: Expert Advisory Panel on the use of Avastin in Metastatic Breast Cancer (EAP-AmBC) - Health Canada

Purpose

The following table summarizes the information about expertise, experience, and affiliations and interests relevant to the Expert Advisory Panel on Avastin mandate declared by panel members. Health Canada considered these declarations as part of the appointment process.

This summary is available as part of Health Canada's commitment to be transparent about the membership of its advisory bodies.

Assessment of affiliations and interests prior to each meeting

Prior to each committee meeting, the advisory body Chair and executive secretary assess each member's affiliations and interests, including direct financial interests, as they may apply to agenda items. Based on this review, they will decide, if necessary, to limit a member's participation in all or part of the meeting agenda, and will inform the member of this decision. As well, on receipt of the meeting agenda, members are expected to review their own affiliations and interests against agenda items and advise the Chair and secretariat if they see a potential cause for concern regarding the integrity and objectivity of their participation.

Members are expected to report promptly any changes in their circumstances as reported on the Affiliations and Interests Declaration Form to the secretariat and the Chair of the advisory body. Health Canada also asks members to review their affiliations and interests declaration on an annual basis.

In accordance with sections 3.2 to 3.6 of the Health Canada Policy on External Advisory Bodies, a person with a direct financial interest in a matter on the advisory body agenda may not participate in discussions with respect to that item, but they may participate in discussions regarding policy, management, or program development as they relate to the mandate of the advisory body.

Indicated [sector/perspective] and expertise/experience

  • Sector/perspective:
    • health professional
    • industry
    • patient
    • research/academia
  • Expertise/experience:
    • medical oncology, specialization in breast cancer
    • patient representation
  1. Direct financial interests
    • Current employment, investments in companies, partnerships, equity, royalties, joint ventures, trusts, real property, stocks, shares, or bonds that relate to the mandate of the advisory body.
  2. Indirect financial interests
    1. Within the past five years, payment from the regulated industry for work done or being done, including past employment, contracts, or consulting; or financial support, including research support, personal education grants, contributions, fellowships, sponsorships, and honoraria.Footnote 1
    2. Within the past five years, materials, discounted products, gifts, or other benefits, or attendance at meetings where all or part of the travel and accommodation costs were provided by a party with an interest in the mandate of the advisory body.Footnote 2
    3. Within the last three years, grants or other funding from a party with an interest in the mandate of the advisory body to any of the organizations where you are currently employed or participate in internal decision making.Footnote 3
  3. Intellectual interests
    1. Within the last five years, any formal advice or opinion to industry, a government organization, or a non-government organization.
    2. Within the last five years, any published or publicly stated point of view.
    3. Current professional or volunteer affiliations, such as membership of professional societies, lobbying, public interest, or advocacy groups.
  4. Other
    • Any other affiliations and interests or potential circumstances that might give a well-informed member of the public reasonable grounds for concern regarding the integrity and objectivity of your participation.
Summary of responses
Name and indicated [sector/perspective] and expertise/experience Summary of responses
Maureen E. Trudeau, MA, MD, FRCPC Health professional / Academia;
Oncology / Research
1a.
No
2a.
Yes
2b.
Yes
2c.
Yes
3a.
Yes
3b.
No
3c.
No
4a.
No
Comments
Attended two scientific advisory board meetings for a pharmaceutical company in the last 5 years. Received travel and accommodation support to attend a breast cancer symposium from a pharmaceutical company. The Odette Cancer Centre Systemic Treatment Program received funding by the pharmaceutical industry for research related to chemotherapy delivery. Member of Committee to Evaluate Drugs, Cancer Care Ontario Subcommittee. Vice-chair of the Expert Review Committee for the pan Canadian Drug Review (pCODR).
Diana M. Ermel Patient;
Patient advocacy & interests
1a.
No
2a.
No
2b.
No
2c.
Yes
3a.
Yes
3b.
No
3c.
Yes
4a.
Yes
Comments
Past president of the Canadian Breast Cancer Network (CBCN). CBCN has received unencumbered funds from the pharmaceutical industry and one educational grant for the development of the Breast Cancer Wait Times in Canada Report Card 2008. Gave presentation to the Government of Canada's Standing Committee on Health regarding Common Drug Review and Joint Oncology Drug Review. Gave a public point of view on a cancer drug in a press release in May 2009.
Kong Khoo MD, FRCPC Health professional / Academia;
Medical Oncology / Hematology / Research
1a.
No
2a.
No
2b.
No
2c.
Yes
3a.
Yes
3b.
No
3c.
No
4a.
No
Comments
Volunteer board member and Vice-Chair of the Cancer Advocacy Coalition of Canada (CACC) which receives unrestricted funds from the pharmaceutical industry. Provided advice at Public Policy Forums on Cancer Drug Access in 2009 and 2010. The CACC Annual Report Cards (2005- 2009) have reported on access to Avastin for colorectal cancer and variability in access and funding in different provinces.
Dianne Moore, BA Patient;
Patient advocacy & interests
1a.
No
2a.
No
2b.
Yes
2c.
Yes
3a.
No
3b.
No
3c.
Yes
4a.
No
Comments
From 1998 - 2008, owned stocks purchased with personal funds from a pharmaceutical company. Received travel expense for stakeholder training from the pharmaceutical industry as a board member of the Canadian Breast Cancer Network (CBCN). The CBCN board of members received travel funds for stakeholder training from the pharmaceutical industry.
Lynne Nakashima, BSc(Pharm), PhD Health professional;
Pharmacology / Oncology
1a.
No
2a.
No
2b.
No
2c.
No
3a.
No
3b.
No
3c.
Yes
4a.
No
Comments
Member of the Canadian Association of Pharmacy in Oncology (CAPhO) and International Society of Oncology Pharmacy Practice (ISOPP).
Wendy R. Parulekar, MD, FRCPC Health professional / Academia;
Medical Oncology / Research
1a.
No
2a.
No
2b.
No
2c.
No
3a.
No
3b.
No
3c.
No
4a.
No
Comments
None
Ian F. Tannock, MD, FRCPC, PhD Health professional / Academia;
Oncology / Research
1a.
No
2a.
No
2b.
No
2c.
No
3a.
No
3b.
Yes
3c.
No
4a.
No
Comments
Published a paper titled, "Addition of Bevacizumab to Chemotherapy for Treatment of Solid Tumors : Similar Results but Different Conclusions" in the Journal of Clinical Oncology, Volume 29, Number 3, January 20, 2011

Page details

Date modified: